MAPT and Alzheimer disease: Given caspase-6 cleaved tau abundance in AD but scarcity in 4R tauopathies, it is worth testing if a CSF assay for caspase-6 cleaved tau performs better in discriminating AD from 4R tauopathies than phospho-tau based assays.